New TAF-Based HIV Treatment Odefsey Approved

Article

The FDA has approved emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg as a new treatment for HIV-1 infection in certain patients.

The FDA has approved emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg (Odefsey) as a new treatment for HIV-1 infection in certain patients.

Odefsey is Gilead’s second tenofovir alafenamide-based HIV regimen to receive FDA approval, and it is the smallest pill of any single-tablet regimen for HIV.

The treatment is designed for patients who are aged 12 years or older, have no antiretroviral treatment history, and have HIV-1 RNA levels ≤100,000 copies/mL. Odefsey can also be used as a replacement for a stable antiretroviral regimen for patients who are virologically suppressed for at least 6 months with no history of treatment failure.

For patients with estimated creatinine clearance of ≥30 mL per minute, no dosage adjustment of Odefsey is necessary.

Pharmacists should make sure patients are aware that the treatment carries a boxed warning about the risks for lactic acidosis/severe hepatomegaly with steatosis and post-treatment acute exacerbation of hepatitis B.

“As people are living longer with HIV, there is an increasing need to develop new treatments that are tolerable and help address long-term health for patients,” said John C. Martin, PhD, chairman and CEO of Gilead Sciences, in a press release. “Odefsey’s safety, efficacy, and tolerability profile offers a new treatment option to support the needs of a range of patients and represents Gilead’s commitment to innovation in the field of HIV.”

The FDA’s nod to Odefsey was based on a bioequivalence study showing that the treatment lead to similar drug levels of emtricitabine and tenofovir alafenamide in the blood as Genvoya, and similar rilpivirine levels as Edurant.

Recent Videos
Image credit:  Gorodenkoff | stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com